Biocept Forms Clinical Advisory Board of World-Renowned Oncologists
"We have created some of the most advanced blood-based technology for profiling and monitoring cancer and, as we grow, we are continually seeking ways to increase the use of our tests in the clinical setting," said Biocept SVP and Senior Medical Director
Members of the
Jenny Chang , MD - Director ofHouston Methodist Cancer Center andEmily Herrmann Chair inCancer Research inHouston ,Dr. Chang is world-renown for her work in clinical research.Michael Kosty , MD - Medical Director of the Cancer Center atScripps Clinic andScripps Green Hospital inLa Jolla, Calif. ,Dr. Kosty is a seasoned hematologist and oncologist who has specialized in lung and prostate cancer for nearly 20 years.Edgardo S. Santos , MD, FACP - Medical Director ofCancer Research and co-leader of the Thoracic and Head & Neck Cancer programs at The Eugene M. & Christine E. Lynn Cancer Institute ofBoca Raton Regional Hospital inBoca Raton, Florida .Dr. Santos also serves on the staff of several hospitals in the area.Lee S. Schwartzberg , MD, FACP - Executive Director Medical Oncologist and Hematologist at theUniversity of Tennessee's West Cancer Center inMemphis ,Dr. Schwartzberg is an award-winning oncologist who has published more than 150 articles in peer-reviewed journals.
"Establishing a
About
Forward-Looking Statements
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to the number of cancer cases diagnosed in 2016, our ability
to improve outcomes for cancer patients and enhance individual treatments of cancer, our ability to expand our physician customer base and support usage of our liquid biopsy tests, and our plans to introduce CLIA-validated tests for other solid tumors in the near term, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our
Logo - http://photos.prnewswire.com/prnh/20151013/276540LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biocept-forms-clinical-advisory-board-of-world-renowned-oncologists-300243105.html
SOURCE
News Provided by Acquire Media